TY  - RPRT
TI  - Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in FLT3, TP53, and MUC4 mutations
AU  - Gholizadeh, E.
AU  - Zangene, E.
AU  - Parsons, A.
AU  - Kontro, M.
AU  - Heckman, C. A.
AU  - Jafari, M.
PY  - 2024
DO  - 10.1101/2024.12.31.630711
UR  - https://www.biorxiv.org/content/10.1101/2024.12.31.630711v1
ID  - 10.1101/2024.12.31.630711
ER  -